GENE ONLINE|News &
Opinion
Blog

2021-09-14|

MD Anderson to Develop Microbiome Cancer Therapeutics with CRISPR Gene-Editing

by Tyler Chen
Share To

Immunotherapy uses checkpoint inhibitors to block the checkpoint protein on immune cells, bolstering the immune system’s ability to target cancerous cells more effectively. The therapy brings huge benefits in treating cancer patients but sometimes comes with serious side effects.

 

Gut Microbes Linked to Checkpoint Inhibitor Toxicity

The University of Texas MD Anderson Cancer Center released a study in July identifying specific gut microbes that are associated with the toxicity from combining CTLA-4 and PD-1 targeting checkpoint inhibitors in melanoma patients.

The study, published in Nature Medicine, suggested that combining checkpoint inhibitors with either IL-1R inhibition or edited gut microbiota are two potential strategies to deal with toxicity, creating a positive outlook for microbiome therapeutics in cancer treatment.

 

Developing Microbiome Therapeutics with CRISPR

On September 13, MD Anderson Cancer Center teamed up with Danish biotech SNIPR Biome. They will use CRISPR to edit the genes of specific gut microbiomes to decrease the immune-related side effects of cancer patients who take combined checkpoint inhibitors.

Accomplishing that goal won’t be easy. A human body can harbor trillions of microbes, and making permanent changes to specific microbiota has proven to be tough going. While scientists look towards CRISPR for breakthroughs, the technology poses challenges; for example, microbes don’t usually survive gene editing, and it’s difficult to develop a specific editing tool for them because gut microbiomes are hard to culture in a lab. 

 

A Need to First Identify Microbiome Profiles

The collaboration comes in 2 parts. First, MD Anderson Cancer Center and SNIPR Biome will work together to identify microbiome profiles. Then, they will use SNIPR Biome’s proprietary CRISPR technology to edit the microbiome. It is said the technology can eliminate the specific microbiota without harming the rest of the microbiome. The resulting microbiome therapeutics are expected to regulate gut microbiota in the human body and decrease high-grade adverse events in cancer patients.

As stated by MD Anderson Cancer Center, the therapy will enter preclinical trials during the collaboration which could lead to a potential clinical trial.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Shaping the Future of the Beauty Industry: Can Skin Microbiome Products Succeed Cosmetics?
2021-10-25
Intellia’s CRISPR Drug Claims FDA Orphan Drug Designation to Treat ATTR Amyloidosis
2021-10-22
IPO
Shanghai Startup Poised for $325M IPO on Nasdaq
2021-10-21
LATEST
10x Genomics Eyes Regional Opportunities in Asia-Pacific, Launches First Overseas Manufacturing Hub
2021-10-26
Shaping the Future of the Beauty Industry: Can Skin Microbiome Products Succeed Cosmetics?
2021-10-25
Sanofi, Regeneron’s Dupixent Shines in Phase 3 Trial for Prurigo Nodularis
2021-10-25
ReCode Therapeutics Raises $80 Million in Series B to Advance Gene Therapy & LNP Delivery Platform
2021-10-23
Intellia’s CRISPR Drug Claims FDA Orphan Drug Designation to Treat ATTR Amyloidosis
2021-10-22
Sio Gene Therapies Touts Positive Safety and Biomarker Data for GM1 Gangliosidosis Candidate
2021-10-22
Daiichi Sankyo to Launch mRNA Covid-19 Vaccine in 2022, Shionogi Presents Clinical Results of Covid-19 Oral Drug
2021-10-22
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!